IL50597A - Pharmaceutical preparations containing p)] - 2] - 2 - chloro-a - methyl - a - phenylbenzyl (- oxy [ethyl [- 1 - methylpyrrolidine - Google Patents
Pharmaceutical preparations containing p)] - 2] - 2 - chloro-a - methyl - a - phenylbenzyl (- oxy [ethyl [- 1 - methylpyrrolidineInfo
- Publication number
- IL50597A IL50597A IL50597A IL5059773A IL50597A IL 50597 A IL50597 A IL 50597A IL 50597 A IL50597 A IL 50597A IL 5059773 A IL5059773 A IL 5059773A IL 50597 A IL50597 A IL 50597A
- Authority
- IL
- Israel
- Prior art keywords
- active agent
- composition according
- composition
- administration
- agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 239000013543 active substance Substances 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- DLNKOYKMWOXYQA-UHFFFAOYSA-N 2-amino-1-phenylpropan-1-ol Chemical compound CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 16
- 150000003839 salts Chemical group 0.000 claims description 16
- 239000012458 free base Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 15
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 14
- 229960000395 phenylpropanolamine Drugs 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008024 pharmaceutical diluent Substances 0.000 description 3
- 229940075065 polyvinyl acetate Drugs 0.000 description 3
- 239000011118 polyvinyl acetate Substances 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- -1 aliphatic acids Chemical class 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001319 vasomotor rhinitis Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010064948 Viral rhinitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1877072 | 1972-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL50597A true IL50597A (en) | 1977-03-31 |
Family
ID=4435189
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL50597A IL50597A (en) | 1972-12-22 | 1973-12-21 | Pharmaceutical preparations containing p)] - 2] - 2 - chloro-a - methyl - a - phenylbenzyl (- oxy [ethyl [- 1 - methylpyrrolidine |
| IL43883A IL43883A (en) | 1972-12-22 | 1973-12-21 | Pharmaceutical preparations containing P)] - 2] -2-chloro-A-methyl-A-phenylbenzyl (- oxy [ethyl [-1-methylpyrrolidine together with sympathomimetic) |
| IL50597A IL50597A0 (en) | 1972-12-22 | 1976-10-01 | Pharmaceutical compositions comprising 1-methyl-2-(2-(a-methyl-p-chlorodiphenylmethoxy)-ethyl) pyrrolidine |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL43883A IL43883A (en) | 1972-12-22 | 1973-12-21 | Pharmaceutical preparations containing P)] - 2] -2-chloro-A-methyl-A-phenylbenzyl (- oxy [ethyl [-1-methylpyrrolidine together with sympathomimetic) |
| IL50597A IL50597A0 (en) | 1972-12-22 | 1976-10-01 | Pharmaceutical compositions comprising 1-methyl-2-(2-(a-methyl-p-chlorodiphenylmethoxy)-ethyl) pyrrolidine |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3933999A (cs) |
| AT (1) | AT344879B (cs) |
| BE (1) | BE808917A (cs) |
| CS (1) | CS214857B2 (cs) |
| DE (1) | DE2362783C2 (cs) |
| ES (1) | ES421642A1 (cs) |
| FR (1) | FR2211248B1 (cs) |
| GB (2) | GB1454389A (cs) |
| HK (1) | HK53580A (cs) |
| HU (1) | HU166632B (cs) |
| IE (1) | IE40494B1 (cs) |
| IL (3) | IL50597A (cs) |
| NL (1) | NL7317300A (cs) |
| PH (1) | PH11667A (cs) |
| SE (1) | SE413459B (cs) |
| ZA (1) | ZA739653B (cs) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648358A (en) * | 1996-03-05 | 1997-07-15 | Mitra; Sekhar | Compositions and methods for treating respiratory disorders |
| RU2205638C1 (ru) * | 2002-05-07 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Антигистаминное средство "бравегил" |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097212A (en) * | 1963-07-09 | N-methyl-z- |
-
1973
- 1973-12-14 SE SE7316967A patent/SE413459B/xx unknown
- 1973-12-17 US US05/425,121 patent/US3933999A/en not_active Expired - Lifetime
- 1973-12-18 NL NL7317300A patent/NL7317300A/xx not_active Application Discontinuation
- 1973-12-18 DE DE2362783A patent/DE2362783C2/de not_active Expired
- 1973-12-18 GB GB5844273A patent/GB1454389A/en not_active Expired
- 1973-12-18 GB GB2139076A patent/GB1454390A/en not_active Expired
- 1973-12-20 FR FR7345731A patent/FR2211248B1/fr not_active Expired
- 1973-12-20 ES ES421642A patent/ES421642A1/es not_active Expired
- 1973-12-20 HU HUSA2576A patent/HU166632B/hu unknown
- 1973-12-20 IE IE2309/73A patent/IE40494B1/xx unknown
- 1973-12-20 BE BE139115A patent/BE808917A/xx not_active IP Right Cessation
- 1973-12-20 PH PH15339A patent/PH11667A/en unknown
- 1973-12-21 IL IL50597A patent/IL50597A/en unknown
- 1973-12-21 AT AT1072273A patent/AT344879B/de active
- 1973-12-21 ZA ZA00739653A patent/ZA739653B/xx unknown
- 1973-12-21 IL IL43883A patent/IL43883A/en unknown
- 1973-12-21 CS CS738911A patent/CS214857B2/cs unknown
-
1976
- 1976-10-01 IL IL50597A patent/IL50597A0/xx unknown
-
1980
- 1980-09-25 HK HK535/80A patent/HK53580A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US3933999A (en) | 1976-01-20 |
| IE40494B1 (en) | 1979-06-20 |
| HK53580A (en) | 1980-10-03 |
| GB1454390A (en) | 1976-11-03 |
| PH11667A (en) | 1978-05-19 |
| ES421642A1 (es) | 1976-09-01 |
| FR2211248B1 (cs) | 1977-09-02 |
| DE2362783C2 (de) | 1984-11-29 |
| HU166632B (cs) | 1975-04-28 |
| AT344879B (de) | 1978-08-10 |
| GB1454389A (en) | 1976-11-03 |
| BE808917A (fr) | 1974-06-20 |
| IL50597A0 (en) | 1976-12-31 |
| CS214857B2 (en) | 1982-06-25 |
| FR2211248A1 (cs) | 1974-07-19 |
| SE413459B (sv) | 1980-06-02 |
| NL7317300A (cs) | 1974-06-25 |
| AU6387473A (en) | 1975-06-26 |
| IE40494L (en) | 1974-06-22 |
| IL43883A (en) | 1977-03-31 |
| ATA1072273A (de) | 1977-12-15 |
| DE2362783A1 (de) | 1974-06-27 |
| IL43883A0 (en) | 1974-03-14 |
| ZA739653B (en) | 1975-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4753789A (en) | Method for treating nausea and vomiting | |
| JP4212149B2 (ja) | 医薬 | |
| US4309406A (en) | Sustained release pharmaceutical compositions | |
| US4309405A (en) | Sustained release pharmaceutical compositions | |
| WO1994002150A1 (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| MXPA00012957A (es) | Composicion para dosis oral de liberacion extendida. | |
| US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| HRP20040352A2 (en) | Use of flibanserin in the treatment of sexual disorders | |
| GB2053682A (en) | Sustained release pharmaceutical compositions | |
| US5578628A (en) | Medicaments for the treatment of nausea and vomiting | |
| EP3609500A1 (en) | Treatment of adipocytes | |
| SK15472001A3 (sk) | Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie | |
| CA1069441A (en) | Pharmaceutical composition containing 2,1,3-benzothiazole | |
| US4032637A (en) | Method of promoting sleep | |
| JPH04346929A (ja) | 光に安定なメシル酸ブロモクリプチン製剤 | |
| IL50597A (en) | Pharmaceutical preparations containing p)] - 2] - 2 - chloro-a - methyl - a - phenylbenzyl (- oxy [ethyl [- 1 - methylpyrrolidine | |
| AU633496B2 (en) | Composition and method for treatment of gastrointestinal disorders | |
| BRPI0615046A2 (pt) | uso de um composto, e, formulação para administração oral | |
| US5482716A (en) | Medicaments | |
| TW383222B (en) | Pharmaceutical composition of bicycloheptane derivatives | |
| US4256747A (en) | Antiphlogistic pharmaceutical compositions and method of use | |
| CA2020171C (en) | Gastroprotective pharmaceutical preparations containing n-benzyl-n-((1s,5s)-6,6-dimethylbicyclo[3,1,1]-hept-2-ylethoxy-ethyl)-morpholinium salts | |
| US4363809A (en) | Organic compounds | |
| US4225605A (en) | Ergolene or ergoline compounds for treating congestive heart failure | |
| US3851062A (en) | Method of suppressing weight gain |